Picture1.jpg
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
May 08, 2024 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager,...
cmi_logo.png
[Latest] Global Hair Styling Tools Market Size/Share Worth USD 25.7 Billion by 2033 at a 4.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 07, 2024 14:40 ET | Custom Market Insights
Austin, TX, USA, May 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hair Styling Tools Market Size, Trends and Insights By Type (Hair Dryers, Hair...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
May 07, 2024 07:30 ET | Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Logo.png
Coda Octopus Group Announces Launch of AI-Based Digital Audio Communications System “Voice HUB-4” After Successful Tests with Naval Customers.
April 29, 2024 08:00 ET | Coda Octopus Group, Inc.
ORLANDO, FL, April 29, 2024 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in 3D/4D/5D/6D imaging sonar technology for real time subsea...
IMG_5056
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 
April 17, 2024 10:15 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
logo.png
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
April 16, 2024 09:00 ET | Autonomix Medical, Inc.
Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity Company developing potential breakthrough two-fold technology that can...
cmi_logo.png
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 15, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...
tiziana-logo.png
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
cmi_logo.png
[Latest] Global Beauty Supplement Market Size/Share Worth USD 8.2 Billion by 2033 at a 12.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 01, 2024 11:30 ET | Custom Market Insights
Austin, TX, USA, April 01, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Beauty Supplement Market Size, Trends and Insights By Form (Tablets, Capsules,...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
March 27, 2024 08:00 ET | Palisade Bio, Inc.
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...